CORRIGENDUM

Cancer drug developers counteract kinase gatekeeper mutations

Asher Mullard

Nature Reviews Drug Discovery **14**, 667–668 (2015)

The text was revised to clarify that the first published report of a T790M EGFR inhibitor came from Nathanael Gray's lab.